Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of September 2017, specifically dated September 18, 2017. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material event disclosed is the filing of a patent application on September 18, 2017. This application seeks to protect the use of the company's drugs and other ligands targeting the A3 adenosine receptor (A3AR) for the treatment of cytokine release syndrome (CRS).
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" from the attached press release (Exhibit 99.1). No specific financial guidance, management commentary on operations, or detailed risk factors are provided within the text of this specific Form 6-K document.
Investor Verification Checklist
- Verify the details of the patent application for A3AR ligands targeting cytokine release syndrome (CRS) in the attached press release (Exhibit 99.1).
- Review the incorporated "Forward Looking Statements" for potential risks associated with the patent filing and drug development.
- Confirm the status of the company's Registration Statements on Form F-3 (File Nos. 333-195124, 333-199033, 333-204795, and 333-209037) as updated by this filing.